SCHEMBL1397690

SCHEMBL1397690

NC(=O)c1cccc(N2CCCCC2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.72
ALDH1A1 P00352 3/20 0.72
HPGD P15428 2/20 0.72
HSD17B10 Q99714 2/20 0.72
KDM4E B2RXH2 1/20 0.72
MEN1 O00255 1/20 0.72
KMT2A Q03164 1/20 0.72
KMO O15229 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.51
L3MBTL3 Q96JM7 1/20 0.51
PARP1 P09874 6/20 0.50
NPC1 O15118 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
PKM P14618 2/20 0.50
TP53 P04637 2/20 0.50
MAPT P10636 2/20 0.50
RAB9A P51151 2/20 0.50
LMNA P02545 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30290422 1.00 GAA (0.72) GAAALDH1A1HPGDHSD17B10KDM4E
Hydrochloric Acid SCHEMBL4630423 0.98 GAA (0.70) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL1397363 0.98 GAA (0.74) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL29630979 0.86 ALDH1A1 (0.96) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3105857 0.86 ALDH1A1 (0.96) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL1517128 0.86 ALDH1A1 (0.96) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3721909 0.84 ALDH1A1 (0.53) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL8349198 0.84 ALDH1A1 (0.70) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL27369622 0.84 ALDH1A1 (0.70) GAAALDH1A1HPGDHSD17B10KDM4E
SCHEMBL27767932 0.84 ALDH1A1 (0.70) GAAALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190834-B1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2011-03-02 EP claimed
EP-2190834-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2010-06-02 EP claimed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP claimed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO claimed
CN-117396462-A Antiviral compounds 英菲克斯治疗有限公司 2024-01-12 CN disclosed
US-20220289724-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-09-15 US disclosed
CN-114302880-A KIF18A inhibitors 美国安进公司 2022-04-08 CN disclosed
CN-102333757-B N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD 2014-11-26 CN disclosed
CN-102333757-A N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD 2012-01-25 CN disclosed
EP-2190834-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2010-06-02 EP disclosed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP disclosed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed
CN-1297559-C Fused bicyclic pyrimidine derivatives KYORIN SEIYAKU KK (JP) 2007-01-31 CN disclosed
CN-1620459-A Fused bicyclic pyrimidine derivatives KYORIN SEIYAKU KK (JP) 2005-05-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289724-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 GAA 1272/4885ALDH1A1 1530/4885HPGD 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.